112 research outputs found
Antigiardial activity of novel triazolyl-quinolone-based chalcone derivatives:when oxygen makes the difference
Giardiasis is a common diarrheal disease worldwide caused by the protozoan parasite
Giardia intestinalis. It is urgent to develop novel drugs to treat giardiasis, due to
increasing clinical resistance to the gold standard drug metronidazole (MTZ). New
potential antiparasitic compounds are usually tested for their killing efficacy against G.
intestinalis under anaerobic conditions, in which MTZ is maximally effective. On the
other hand, though commonly regarded as an âanaerobic pathogen,â G. intestinalis
is exposed to relatively high O2 levels in vivo, living attached to the mucosa of the
proximal small intestine. It is thus important to test the effect of O2 when searching
for novel potential antigiardial agents, as outlined in a previous study [Bahadur et al.
(2014) Antimicrob. Agents Chemother. 58, 543]. Here, 45 novel chalcone derivatives
with triazolyl-quinolone scaffold were synthesized, purified, and characterized by high
resolution mass spectrometry, 1H and 13C nuclear magnetic resonance and infrared
spectroscopy. Efficacy of the compounds against G. intestinalis trophozoites was tested
under both anaerobic and microaerobic conditions, and selectivity was assessed in a
counter-screen on human epithelial colorectal adenocarcinoma cells. MTZ was used as
a positive control in the assays. All the tested compounds proved to be more effective
against the parasite in the presence of O2, with the exception of MTZ that was less
effective. Under anaerobiosis eighteen compounds were found to be as effective as
MTZ or more (up to three to fourfold); the same compounds proved to be up to >100-
fold more effective than MTZ under microaerobic conditions. Four of them represent
potential candidates for the design of novel antigiardial drugs, being highly selective
against Giardia trophozoites. This study further underlines the importance of taking O2
into account when testing novel potential antigiardial compounds
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450
Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor
Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including protease inhibitors (PI). We describe here the case of an HIV-infected patient with PAH, who was co-administered bosentan 125 mg twice daily and sildenafil 40 mg three times per day, together with a ritonavir-boosted PI-based antiretroviral therapy; plasma levels of bosentan, sildenafil, N-desmethylsildenafil, and PI were measured. The patient had a sildenafil Cthrough and Cmax of 276.94 ng/mL and 1733.19 ng/mL, respectively. The Cthrough and the Cmax of bosentan were 1546.53 ng/mL and 3365.99 ng/mL, respectively. The patient was able to tolerate as high sildenafil blood concentrations as 10 times those usually requested and did not report any significant adverse reaction to sildenafil during the follow-up period. Therapeutic drug monitoring should be considered during sildenafil therapy in patients concomitantly treated with ritonavir-boosted PI
Analysis of the dynamics of cryoaggregation by light-scattering spectrometry
Cryoglobulins are proteins that precipitate at temperatures below 37 °C. Cold-induced precipitation of proteins may occur in vivo secondary to several important diseases, and lead to pathological manifestations involving different organs. Cryoprecipitation may be observed in vitro by exposing serum samples, supposed to contain cryoglobulins, to low temperatures, but this needs several days to occur. Protein-protein interactions leading to cryoprecipitation are still poorly understood and the knowledge of the underlying mechanism may be relevant to the understanding of the onset of pathological manifestations. Using light-scattering spectrometry, we studied cryoprecipitation occurring in vitro at different temperatures and cryoglobulin concentrations. We describe the kinetics of the cold-induced precipitation of mixed cryoglobulins, measured as increase in turbidity. The plots obtained demonstrate that the cryoprecipitation did not occur as a single-step reaction, but consisted of four distinct phases where both temperature and cryoglobulin concentration affected the immune complexes formation. Light scatter spectrometry may provide a simple, sensitive and rapid method for the detection of cryoglobulins
Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor
The superoxide reductase from the early diverging eukaryote Giardia intestinalis
Unlike superoxide dismutases (SODs), superoxide reductases (SORs) eliminate superoxide anion (O(2)(center dot-)) not through its dismutation, but via reduction to hydrogen peroxide (H(2)O(2)) in the presence of an electron donor. The microaerobic protist Giardia intestinalis, responsible for a common intestinal disease in humans, though lacking SOD and other canonical reactive oxygen species-detoxifying systems, is among the very few eukaryotes encoding a SOR yet identified. In this study, the recombinant SOR from Giardia (SOR(Gi)) was purified and characterized by pulse radiolysis and stopped-flow spectrophotometry. The protein, isolated in the reduced state, after oxidation by superoxide or hexachloroiridate(IV), yields a resting species (T(final)) with Fe(3+) ligated to glutamate or hydroxide depending on pH (apparent pK(a) = 8.7). Although showing negligible SOD activity, reduced SOR(Gi) reacts with O(2)(center dot-) with a pH-independent second-order rate constant k(1) =1.0 x 10(9) M(-1) s(-1) and yields the ferric-(hydro)peroxo intermediate T(1); this in turn rapidly decays to the T(final) state with pH-dependent rates, without populating other detectable intermediates. Immunoblotting assays show that SOR(Gi) is expressed in the disease-causing trophozoite of Giardia. We propose that the superoxide-scavenging activity of SOR in Giardia may promote the survival of this air-sensitive parasite in the fairly aerobic proximal human small intestine during infection. (C) 2011 Elsevier Inc. All rights reserved
Levels of Interleukinâ15 in Plasma May Predict a Favorable Outcome of Structured Treatment Interruption in Patients with Chronic Human Immunodeficiency Virus Infection
Identification of Early Secretory Antigen Target-6 Epitopes for the Immunodiagnosis of Active Tuberculosis
The early secretory antigenic target (ESAT)-6 purified protein and peptides from Mycobacterium tuberculosis were evaluated as antigens for the immunodiagnosis of tuberculosis (TB). Because the control of TB requires improved diagnostic procedures, efforts have increased to identify Mycobacterium tuberculosisâspecific epitopes for the immunodiagnosis of active TB and to discriminate between active and latent states of infection. Two multiepitopic peptides from ESAT-6 protein were selected by computational analysis. Patients with active TB (7 HIV(+) and 20 HIV(â)) and control patients (17 HIV(+) and 28 HIV(â)) were enrolled. Enzyme-linked immunospot assay analysis for interferon-Îł expression by peripheral blood mononuclear cells was quantified after stimulation with selected ESAT-6 peptides, purified protein derivative, or the intact ESAT-6 protein. During active TB, 20 of 27 patients responded in vitro to ESAT-6 peptides and 23 of 27 patients to purified protein derivative. None of the controls without active TB, including individuals with latent TB infection, recognized ESAT-6 peptides. By contrast, latently infected individuals did respond in vitro to both intact ESAT-6 protein and purified protein derivative. Thus, high T-cell response frequencies to ESAT-6 peptides are present only during active TB and can be used to discriminate between active and latent forms of infection
- âŠ